linjc16/ctgov huggingface dataset:
Ultrasound Assessment of Clear Liquid Intake During Labour

Study Overview
=================
Brief Summary
-----------------
We designed a two arms prospective, randomised, simple blinded trial to compare the impact of clear liquid intake on gastric content before delivery. We hypothesize that there will be no difference between the two groups, leading to safety of clear liquid intake during labour.

Detailed Description
-----------------
Gastric emptying is a major concern for anesthetists in obstetric. In order to prevent the risk of gastric aspiration, we are used to forbid to eat and to drink during labour. However, this behaviour is controversial and some studies have shown that clear liquid intake can be safe during labour. Informations from a bedside ultrasound examination of the stomach content may be a useful tool to balance benefits and risks of such attitude. This technique has recently been shown very promising in pregnant women for the assessment of the gastric volume.

Official Title
-----------------
Fluid Intake During Labour, Ultrasound Evaluation

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Other: Apple juice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any pregnant woman at term Exclusion Criteria: Pathologic pregnancy Twin pregnancy Body mass index above 35 kg/m2 before pregnancy Cervix dilation above 8 cm Refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Apple juice<br>Patient are allowed to drink up to 400 ml of apple juice | Other: Apple juice<br>* Intervention consists in allowing drinks during labour<br>|
| No Intervention: Control<br>Patient are not allowed to drink | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of parturients with a full stomach | A full stomach is defined by an antral area above 300 mm2 evaluated by ultrasound imaging | average of 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parturient comfort | Comfort is evaluated using Labour Agentry Scale | average of 6 hours | 
| Evolution of the antral area | Antral area are measured by gastric ultrasonography at the beginning and at the end of labour | average of 6 hours | 
| Anxiety | Anxiety is measured by a Visual Analogic Scale | average of 6 hours | 
| Pain intensity | Pain is measured by a Visual Analogic Scale | average of 6 hours |
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Official Title
-----------------
Ocular Signs and Symptoms in Patients With Ocular Hypertension or Open-angle Glaucoma Switched From Preserved Latanoprost 0.005% Eye Drops to Preservative Free Tafluprost Eye Drops

Conditions
-----------------
Ocular Hypertension, Open-Angle Glaucoma

Intervention / Treatment
-----------------
* Drug: tafluprost


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Open-lable study with one arm<br> | Drug: tafluprost<br>* prostaglandin analogue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of changes in ocular symptoms and signs | Ocular symptoms include: irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation. Following signs will be evaluated: tear break-up time, corneal and conjunctival fluorescein staining, blepharitis, conjunctival redness and tear secretion (schirmer test). | From Screening (Visit 1) to12 weeks. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcome measures include the assessment of safety and quality of life parameters. | Safety parameters include: best-corrected visual acuity, biomicroscopy, ophthalmoscopy, visual field test, drop discomfort upon instillation, intra ocular pressure, quality of life and adverse events. | From Screening (visit 1) to 12 weeks |
VIDEOLARYNGOSCOPY STUDY OF THE LPEC

Study Overview
=================
Brief Summary
-----------------
Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.

Detailed Description
-----------------
Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.

Official Title
-----------------
Evaluation of the Impact of the Sellick Manoeuvre or Para-tracheal Compression of the Cervical Esophagus on the Displacement of the Laryngeal Mass and the Visualization of the Vocal Cords

Conditions
-----------------
Laryngoscopy

Intervention / Treatment
-----------------
* Procedure: mobilization of the larynx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults patients undergoing general anaesthesia Exclusion Criteria: pregnant women people with facial oropharyngeal abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance between oesophagus and trachea | Distance between oesophagus and trachea | During laryngoscopy procedure |
Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this registry is to obtain case reports of physician experience with the Spiral-Z® graft under routine clinical care.

Official Title
-----------------
Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry

Conditions
-----------------
Abdominal Aortic Aneurysm, Aorto-iliac Aneurysm

Intervention / Treatment
-----------------
* Device: Iliac Leg Graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is implanted with Zenith® Spiral-Z® AAA Iliac Leg Graft. Exclusion Criteria: Patients for whom this device would not normally be considered standard of care.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Abdominal aortic aneurysm<br> | Device: Iliac Leg Graft<br>* Zenith® Spiral-Z® AAA Iliac Leg Graft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess short term and longer term outcomes, including outcomes related to patency, of the Zenith® Spiral-Z® AAA Iliac Leg Graft. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
abdominal aortic aneurysm, iliac leg graft
Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants

Study Overview
=================
Brief Summary
-----------------
This study examines the analgesic efficacy of codeine phosphate. It is compared to placebo in infants receiving morphine after surgery. Codeine may be effective enough to make morphine unnecessary.

Official Title
-----------------
Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants

Conditions
-----------------
Cleft Palate Repair

Intervention / Treatment
-----------------
* Drug: Codeine Phosphate Analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants with cleft palate

Ages Eligible for Study
-----------------
Minimum Age: 4 Months
Maximum Age: 8 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Codeine Phosphate Analgesia|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of morphine used within the first 6h after surgery |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
codeine phosphate analgesia
Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.

Study Overview
=================
Brief Summary
-----------------
Post-operative pain will be measured using a pain diary for one week post-surgery. The purpose is to test the assumption that the arthroscopic technique leads to less post-operative pain and results in shorter hospital stays when compared to the open technique. It is believed that the arthroscopic technique will result in minimal pain when compared to the open technique, allowing this procedure to be performed as day surgery.

Official Title
-----------------
Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ankle osteoarthritis with adequate bone stock Exclusion Criteria: Mental or physical inability to consent or answer pain questions, pre-operative or peri-operative morbidity impairing mobility, pre-operative opioid therapy, non-steroidal anti-inflammatory drugs or steroids within 24 hours before skin incision, kidney or liver dysfunction, morbid obesity, smoking, significant bony deformity, significant loss of bone stock or diabetes with sensory changes will be cause for exclusion.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| scope technique<br> | |
| open technique<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numeric Rating Pain Scale (NRPS) | A scale from 0-10 is used for patients to record the amount of pain they are experiencing at a given time. Multiple questions are asked on a daily basis in a pain diary to report pain in the morning, at night, with movement, before and after pain medication. | recorded for one week post-operatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ankle arthrodesis, pain, arthroscopic technique, ankle osteoarthritis
Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing

Study Overview
=================
Brief Summary
-----------------
Despite significant progress made in identification on numerous genes and gene pathways critical for craniofacial development, several approaches, ie mutation screening of specific candidates, association studies and even genome-wide scans have largely failed to reveal the molecular basis of NS human clefting

Detailed Description
-----------------
Despite significant progress made in identification on numerous genes and gene pathways critical for craniofacial development, several approaches, ie mutation screening of specific candidates, association studies and even genome-wide scans have largely failed to reveal the molecular basis of NS human clefting. Moreover, the efficiency of Whole Exome Sequencing -WES- was proven. The efficiency of WES was proven by the identification of the genes causing Freeman Sheldon and Miller's syndrome, followed by several others. In the Picardy region, management and follow-up of orofacial cleft patients are well-organised by a multidisciplinary team in the university hospital of Amiens. The investigators therefore decided to perform whole exome sequencing (WES) on precisely phenotyped non-syndromic CL/P patients followed in our center.

Official Title
-----------------
Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing GENEPIC

Conditions
-----------------
Cleft Lip and Palate

Intervention / Treatment
-----------------
* Genetic: identification of genetic factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject with a NSCL/P or CL/P of unknown etiology, national health care insurance holders Exclusion Criteria: Subject with a CL/P of known etiology, Subject with a NSCL/P and an IRF6 mutation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Identification of genetic factors<br>Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing | Genetic: identification of genetic factors<br>* Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic factors | Identification of genetic factors implicated in orofacial cleft using whole exome sequencing (WES). | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cleft Lip and Palate, CL/P, WES
Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Study Overview
=================
Brief Summary
-----------------
Efficacy of Methylene blue mediated Photodynamic therapy for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Official Title
-----------------
Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Conditions
-----------------
Lichen Amyloidosis

Intervention / Treatment
-----------------
* Procedure: Methylene blue-mediated photodynamic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, aged > 18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathological findings. Exclusion Criteria: Those with systemic disease associated cutaneous amyloidosis Pregnancy or lactating woman Those who are allergic to urea, olive oil Those who are photosensitive to ultraviolet radiation Those who had been previously treated with any of which -medications, radiation, laser within 3 months and 1 month for topical therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MB-PDT<br> | Procedure: Methylene blue-mediated photodynamic therapy<br>* The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Roughness evaluation by using visioscan | The improvement of roughness during the treatment | Change from baseline roughness at every 2 weeks up to 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Methylene blue, photodynamic therapy, primary cutaneous localized amyloidosis, lichen amyloidosis
Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia

Study Overview
=================
Brief Summary
-----------------
Retrograde cardioplegia during heart surgery is associated with inadequate myocardial protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte apoptosis when compared to antegrade cardioplegia. 20 volunteer patients under going elective aortic valve surgery will be divided in to two groups: 10 patients receiving only antegrade cardioplegia and 10 patients receiving only retrograde cardioplegia. Pre- and post-operatively cardiac MRI and cardiac ultrasound will be performed. During the surgery ventricular muscle samples will be taken in order to assess cardiomyocyte apoptosis. Aims of the study: 1. whether the cardiomyocyte apoptosis is significantly more induced after retrograde cardioplegia than antegrade cardioplegia, 2. whether the amount of apoptotic cardiomyocytes correlates to conventional markers of myocardial injury after cardiac surgery, 3. whether the extent of irreversible myocardial damage by apoptosis correlates to post-ischemic contractile dysfunction after cardiac surgery, as measured with echocardiography, 4. whether the amount of cardiomyocyte apoptosis correlates to long term outcome and cardiac function as measured with MRI.

Conditions
-----------------
Cardiomyocyte Apoptosis

Intervention / Treatment
-----------------
* Procedure: Ventricle muscle tissue samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aortic valve stenosis or combined aortic valve disease Exclusion Criteria: angiographically verified hemodynamically significant coronary artery disease impaired left ventricular function (left ventricular ejection fraction <50%) surgery including additional procedures other than aortic valve replacement cancer

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiomyocyte apoptosis<br>Elective aortic valve replacement patience | Procedure: Ventricle muscle tissue samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac MRI, Cardiac ultrasound, Cardiac surgery